Previous close | 7.90 |
Open | 7.90 |
Bid | 10.00 |
Ask | 10.80 |
Strike | 50.00 |
Expiry date | 2024-08-16 |
Day's range | 7.90 - 7.90 |
Contract range | N/A |
Volume | |
Open interest | 32 |
NEW YORK, May 02, 2024--Establishment Labs Holdings Inc. (NASDAQ: ESTA), a global medical technology company dedicated to improving women’s health and wellness, principally in breast aesthetics and reconstruction, noted the presentation today of an update on the Motiva US IDE Study. The update will include four-year patient follow-up data for primary augmentation subjects. The Medical Director of the Study, Dr. Caroline Glicksman, who is also an Investigator in the Study, will present the result
NEW YORK, May 01, 2024--Establishment Labs Holdings Inc. (NASDAQ: ESTA), a global medical technology company dedicated to improving women’s health and wellness, principally in breast aesthetics and reconstruction, announced today that Jeff Ehrhardt has joined the company as General Manager of North America. After having spent over 25 years at Allergan Aesthetics, an Abbvie Company, Mr. Ehrhardt joins Establishment Labs with responsibilities including the anticipated launch of Motiva implants in
NEW YORK, April 24, 2024--Establishment Labs Holdings Inc. (NASDAQ: ESTA), a global medical technology company dedicated to improving women’s health and wellness, principally in breast aesthetics and reconstruction, plans to announce its financial results for the quarter ended March 31, 2024 after the market closes on Wednesday, May 8, 2024, and will host a conference call at 4:30 pm ET that day to discuss those results.